The letter about the article “Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study” that discusses some points about methodology, outcome measures, and results.
GluePNeehoffSBeagleholeB, et al. (2024) Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. J Psychopharmacol38: 162–167. DOI: 10.1177/02698811241227026.
2.
MitchellAJMeaderNSymondsP (2010) Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: A meta-analysis. J Affect Disorders126: 335–348. DOI: 10.1016/j.jad.2010.01.067.
3.
ZhouYSunWZhangG, et al. (2021) Ketamine alleviates depressive symptoms in patients undergoing intracranial tumor resection: A randomized controlled trial. Anesth Analg133: 1588–1597. DOI: 10.1213/ANE.0000000000005752.
